Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

The more people become aware of CNAT and become bullish about the stock, the more whoever is controlling the price tries to keep it down.
This PPS manipulation used to be bad news for CNAT because it made trial financing more and more dilutive.
The good news now is that there is no more dilution to come as the trials and commercialization are now (subject to NVS option exercise) fully funded but CNAT is also going to get $650M plus royaltoes that could go as high as 25-30% on net sales.
So Emricasan success will now only depend on its efficacy and safety, and the trials have given strong hints of efficacy. Moreover Novartis has deeply looked into it and willing to invest more than $1B just to get the drug approved.
So we can only thank MM for these prices, and I hope they will continue much longer, as they allow us to buy a stock that could be worth 1,000 times current PPS in 5 years time